Home › Funds › Syncona Portfolio Ltd › AUTL
Syncona Portfolio Ltd position in AUTL
AUTOLUS THERAPEUTICS LTD · Health Care
Syncona Portfolio Ltd reported holding 16,640,720 shares of AUTL (AUTOLUS THERAPEUTICS LTD) in its Q3 2026 13F filing — a position valued at US$32.3M, representing 100.00% of its reported portfolio and ranking #1 among its reported holdings. Syncona Portfolio Ltd has disclosed AUTL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Syncona Portfolio Ltd's AUTL position evolved
Syncona Portfolio Ltd first disclosed a stake in AUTL in Q3 2023 at 21,346,829 shares (US$49.7M). The position peaked in Q4 2023 at 21,346,829 shares, worth US$137.5M. Across 13 filings, Syncona Portfolio Ltd increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 10 time(s). The most recent filing (Q3 2026) shows 16,640,720 shares valued at US$32.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 21.35M | $49.74M | New |
| Q4 2023 | 21.35M | $137.47M | Hold |
| Q1 2024 | 21.35M | $136.19M | Hold |
| Q2 2024 | 21.35M | $74.29M | Hold |
| Q3 2024 | 18.55M | $67.35M | Reduce |
| Q4 2024 | 16.64M | $39.11M | Reduce |
| Q1 2025 | 16.64M | $25.79M | Hold |
| Q2 2025 | 16.64M | $37.94M | Hold |
| Q3 2025 | 16.64M | $27.12M | Hold |
| Q4 2025 | 16.64M | $33.12M | Hold |
| Q1 2026 | 16.64M | $22.96M | Hold |
| Q2 2026 | 16.64M | $26.63M | Hold |
| Q3 2026 | 16.64M | $32.28M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AUTL and 13F data
AUTL (AUTOLUS THERAPEUTICS LTD) is a Health Care company. 18 other funds we track also report a position in AUTL — the largest reported positions include MAK CAPITAL ONE LLC (US$53.8M), ARMISTICE CAPITAL, LLC (US$24.0M), Tetragon Partners GP Ltd (US$15.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AUTL
- MAK CAPITAL ONE LLC 33.62M sh · $53.79M · Q2 2026
- ARMISTICE CAPITAL, LLC 15.00M sh · $24.00M · Q2 2026
- Tetragon Partners GP Ltd 9.50M sh · $15.20M · Q2 2026
- Frazier Life Sciences Management, L.P. 4.45M sh · $7.12M · Q2 2026
More on Syncona Portfolio Ltd
FAQ
How long has Syncona Portfolio Ltd held AUTL?
Syncona Portfolio Ltd has disclosed AUTL holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Syncona Portfolio Ltd's current position in AUTL?
As of Q3 2026, Syncona Portfolio Ltd holds 16.64M shares of AUTL (AUTOLUS THERAPEUTICS LTD), valued at $32.28M, representing 100.00% of its reported portfolio and ranking #1.
Has Syncona Portfolio Ltd been buying or selling AUTL?
In the latest 13F filing (Q3 2026), Syncona Portfolio Ltd held unchanged its position in AUTL. The position peaked in Q4 2023 at 21.35M shares.
Which other funds hold AUTL?
Other major institutional holders of AUTL include MAK CAPITAL ONE LLC, ARMISTICE CAPITAL, LLC, Tetragon Partners GP Ltd, among 18 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.